Internal Medicine, Endocrinology, Diabetes, & Metabolism · Gulfport, MS
NPI
1194776286
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
4540 W Railroad St
Gulfport, MS, 39501
Phone (228) 867-6062
Groups this clinician bills Medicare through
Medicare paid, 2024
$89K
2,269 services
Medicare patients, 2024
728
Average age 73
Drug cost, 2024
$6.5M
7,812 prescriptions
Company payments, 2025
$63K
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark D Borchelt was code 99213 (office e&m - established), 771 times for 562 patients. In total Mark D Borchelt billed 2,269 services in 11 codes, and Medicare paid $89K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-06-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 771 | 562 | $44.50 | $34K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 693 | 462 | $11.94 | $8,273 |
| 99214 Office E&M - Established | Office | 510 | 276 | $65.62 | $33K |
| 95251 Test - Miscellaneous | Office | 162 | 79 | $24.75 | $4,009 |
| 99203 Office E&M - New | Office | 61 | 61 | $57.83 | $3,528 |
| 99204 Office E&M - New | Office | 55 | 55 | $90.85 | $4,997 |
By year: 2022 $81K for 1,572 services; 2023 $74K for 1,440 services; 2024 $89K for 2,269 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark D Borchelt prescribed most often to Medicare patients was Levothyroxine Sodium, with 788 prescriptions and refills. In total Mark D Borchelt wrote 7,812 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 788 | 2,027 | 209 | $6,754 |
| Mounjaro Tirzepatide | 701 | 884 | 140 | $926K |
| Ozempic Semaglutide | 556 | 898 | 132 | $854K |
| Jardiance Empagliflozin | 502 | 1,047 | 130 | $606K |
| Rosuvastatin Calcium Generic | 355 | 956 | 118 | $3,704 |
| Tresiba Flextouch U-200 Insulin Degludec | 345 | 737 | 95 | $359K |
| Trulicity Dulaglutide | 320 | 468 | 78 | $450K |
| Metformin Hcl Generic | 292 | 754 | 88 | $1,470 |
| Synthroid Levothyroxine Sodium | 235 | 523 | 53 | $21K |
| Pioglitazone Hcl Generic | 210 | 484 | 56 | $1,871 |
| Methimazole Generic | 172 | 291 | 37 | $1,620 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 138 | 377 | 64 | $14K |
| Ezetimibe Generic | 137 | 369 | 53 | $2,532 |
| Glimepiride Generic | 112 | 247 | 28 | $398 |
| Farxiga Dapagliflozin Propanediol | 110 | 179 | 21 | $95K |
Brand drugs: 4,603 claims; generic drugs: 2,754 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark D Borchelt $63K ($63K in general payments such as food, travel and fees) from 31 companies. The largest payer was Lilly USA, LLC with $43K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 87 | $43K |
| Amgen Inc. AMGN | 29 | $9,023 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 25 | $7,645 |
| Abbott Laboratories ABT | 16 | $758 |
| Novo Nordisk Inc NVO | 21 | $368 |
| Xeris Pharmaceuticals, Inc. | 14 | $270 |
| Medtronic, Inc. MDT | 13 | $261 |
| Dexcom, Inc. DXCM | 13 | $229 |
| Beta Bionics, Inc. BBNX | 12 | $190 |
| Corcept Therapeutics CORT | 10 | $163 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.